HC Wainwright reissued their buy rating on shares of IO Biotech (NASDAQ:IOBT - Free Report) in a report published on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright also issued estimates for IO Biotech's Q1 2025 earnings at ($0.50) EPS, Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.42) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.91) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.39) EPS, FY2028 earnings at ($0.39) EPS, FY2029 earnings at ($0.13) EPS and FY2029 earnings at ($0.13) EPS.
Separately, Piper Sandler upgraded IO Biotech to a "strong-buy" rating in a report on Wednesday, March 12th.
Check Out Our Latest Stock Report on IOBT
IO Biotech Trading Down 2.1 %
NASDAQ IOBT traded down $0.02 during trading on Tuesday, reaching $0.98. The company's stock had a trading volume of 180,208 shares, compared to its average volume of 271,235. The stock has a market capitalization of $64.84 million, a PE ratio of -0.72 and a beta of 0.22. The business has a 50-day moving average price of $0.97 and a 200-day moving average price of $0.98. IO Biotech has a 1-year low of $0.66 and a 1-year high of $1.79.
Institutional Trading of IO Biotech
Large investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new position in IO Biotech during the 4th quarter worth $249,000. Dauntless Investment Group LLC acquired a new stake in IO Biotech in the 4th quarter valued at approximately $688,000. XTX Topco Ltd acquired a new stake in IO Biotech in the 4th quarter valued at approximately $26,000. Renaissance Technologies LLC increased its position in IO Biotech by 22.5% in the 4th quarter. Renaissance Technologies LLC now owns 118,800 shares of the company's stock worth $109,000 after buying an additional 21,800 shares during the period. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of IO Biotech during the fourth quarter worth approximately $407,000. 54.76% of the stock is owned by institutional investors.
IO Biotech Company Profile
(
Get Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
See Also
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
